BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 16220294)

  • 1. Elevated hepatocyte paraffin 1 and neprilysin expression in hepatocellular carcinoma are correlated with longer survival.
    Mondada D; Bosman FT; Fontolliet C; Seelentag WK
    Virchows Arch; 2006 Jan; 448(1):35-45. PubMed ID: 16220294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatocyte antigen as a marker of hepatocellular carcinoma: an immunohistochemical comparison to carcinoembryonic antigen, CD10, and alpha-fetoprotein.
    Chu PG; Ishizawa S; Wu E; Weiss LM
    Am J Surg Pathol; 2002 Aug; 26(8):978-88. PubMed ID: 12170084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Canalicular immunostaining of neprilysin (CD10) as a diagnostic marker for hepatocellular carcinomas.
    Borscheri N; Roessner A; Röcken C
    Am J Surg Pathol; 2001 Oct; 25(10):1297-303. PubMed ID: 11688465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination with CK19 Might Increase the Prognostic Power of Hep Par 1 in Hepatocellular Carcinoma after Curative Resection.
    Jin Y; Liang ZY; Zhou WX; Zhou L
    J Invest Surg; 2018 Oct; 31(5):412-419. PubMed ID: 28758812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Expression of glypican-3, hepatocyte antigen, alpha-fetoprotein, CD34 and CD10 in hepatocellular carcinoma: a clinicopathologic analysis of 375 cases].
    Du JL; Wang YL; Shi HY; Guo AT; Wei LX
    Zhonghua Bing Li Xue Za Zhi; 2012 May; 41(5):309-13. PubMed ID: 22883669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocyte expressions in hepatocellular carcinomas, gastrointestinal neoplasms, and non-neoplastic gastrointestinal mucosa: its role as a diagnostic marker.
    Lee HS; Kim WH; Kang GH
    J Korean Med Sci; 2003 Dec; 18(6):842-8. PubMed ID: 14676441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. cDNA arrays and immunohistochemistry identification of CD10/CALLA expression in hepatocellular carcinoma.
    Xiao SY; Wang HL; Hart J; Fleming D; Beard MR
    Am J Pathol; 2001 Oct; 159(4):1415-21. PubMed ID: 11583969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of KIF23 variant 1 expression and relevance as a novel prognostic factor in patients with hepatocellular carcinoma.
    Sun X; Jin Z; Song X; Wang J; Li Y; Qian X; zhang Y; Yin Y
    BMC Cancer; 2015 Dec; 15():961. PubMed ID: 26674738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatocyte paraffin 1 expression in human normal and neoplastic tissues: tissue microarray analysis on 3,940 tissue samples.
    Lugli A; Tornillo L; Mirlacher M; Bundi M; Sauter G; Terracciano LM
    Am J Clin Pathol; 2004 Nov; 122(5):721-7. PubMed ID: 15491968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical characterization of canine hyperplastic hepatic lesions and hepatocellular and biliary neoplasms with monoclonal antibody hepatocyte paraffin 1 and a monoclonal antibody to cytokeratin 7.
    Ramos-Vara JA; Miller MA; Johnson GC
    Vet Pathol; 2001 Nov; 38(6):636-43. PubMed ID: 11732796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic utility of CD10 in differentiating hepatocellular carcinoma from metastatic carcinoma in fine-needle aspiration biopsy (FNAB) of the liver.
    Lin F; Abdallah H; Meschter S
    Diagn Cytopathol; 2004 Feb; 30(2):92-7. PubMed ID: 14755758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined hepatocellular and cholangiocarcinoma originating from the same clone: a pathomolecular evidence-based study.
    Zhao Q; Yu WL; Lu XY; Dong H; Gu YJ; Sheng X; Cong WM; Wu MC
    Chin J Cancer; 2016 Aug; 35(1):82. PubMed ID: 27552844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased STAT4 indicates poor prognosis and enhanced cell proliferation in hepatocellular carcinoma.
    Wang G; Chen JH; Qiang Y; Wang DZ; Chen Z
    World J Gastroenterol; 2015 Apr; 21(13):3983-93. PubMed ID: 25852285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistological evaluation of single small hepatocellular carcinoma with negative staining of monoclonal antibody Hepatocyte Paraffin 1.
    Sugiki T; Yamamoto M; Aruga A; Takasaki K; Nakano M
    J Surg Oncol; 2004 Nov; 88(2):104-7. PubMed ID: 15499598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of CD10 immunochemistry in differentiating hepatocellular carcinoma from metastatic carcinoma of the liver.
    Ahuja A; Gupta N; Kalra N; Srinivasan R; Chawla Y; Rajwanshi A
    Cytopathology; 2008 Aug; 19(4):229-35. PubMed ID: 18070122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HepPar1, MOC-31, pCEA, mCEA and CD10 for distinguishing hepatocellular carcinoma vs. metastatic adenocarcinoma in liver fine needle aspirates.
    Wang L; Vuolo M; Suhrland MJ; Schlesinger K
    Acta Cytol; 2006; 50(3):257-62. PubMed ID: 16780018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis.
    Lu LL; Sun J; Lai JJ; Jiang Y; Bai LH; Zhang LD
    World J Gastroenterol; 2015 Jun; 21(21):6649-59. PubMed ID: 26074703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hep par-1: a novel immunohistochemical marker for differentiating hepatocellular carcinoma from metastatic carcinoma.
    Hanif R; Mansoor S
    J Coll Physicians Surg Pak; 2014 Mar; 24(3):186-9. PubMed ID: 24613115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NGAL and NGALR overexpression in human hepatocellular carcinoma toward a molecular prognostic classification.
    Zhang Y; Fan Y; Mei Z
    Cancer Epidemiol; 2012 Oct; 36(5):e294-9. PubMed ID: 22728279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic impact of CD10 expression in clinical outcome of invasive breast carcinoma.
    Vo TN; Mekata E; Umeda T; Abe H; Kawai Y; Mori T; Kubota Y; Shiomi H; Naka S; Shimizu T; Murata S; Yamamoto H; Ishida M; Tani T
    Breast Cancer; 2015 Mar; 22(2):117-28. PubMed ID: 23575921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.